MYC dysregulation in the progression of multiple myeloma
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
RAS mutations, MYC translocations, APOBEC mutagenesis, and patterns of genomic complexity are the most commonly reported alterations in progressing multiple myeloma.
“Among these, RAS mutations, MYC translocations, APOBEC mutagenesis, and patterns of genomic complexity are the most commonly reported.8,9,11,69,76-83,84”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [81]
In the main text (page unavailable), the paper identifies MYC structural variants and RAS-pathway mutations as progression-related events and reports their frequencies in SMM and MM. It does not address APOBEC mutagenesis or establish that the four listed categories are the most commonly reported alterations; its discussion of complexity concerns some MYC rearrangements, not genomic complexity generally. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Landgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194241 · Cited by 1,127 · see citing works
Self-citationMultiple myeloma: evolving genetic events and host interactions
Kuehl, W. M., & Bergsagel, P. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc746 · Cited by 818 · see citing works
Self-citationCyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
Bergsagel, P. L., Kuehl, W. M., Zhan, F., Sawyer, J. R., Barlogie, B., & Shaughnessy, J. D. (2005) · Blood · doi:10.1182/blood-2005-01-0034 · Cited by 700 · see citing works
Self-citationA monoclonal gammopathy precedes multiple myeloma in most patients
Weiss, B. M., Abadie, J. M., Verma, P. S., Howard, R. S., & Kuehl, W. M. (2009) · Blood · doi:10.1182/blood-2008-12-195008 · Cited by 568 · see citing works
Self-citationMYC Deregulation in Primary Human Cancers
Kalkat, M., Melo, J. D., Hickman, K. A., Lourenco, C., Redel, C., Resetca, D., Tamachi, A., Tu, W. B., & Penn, L. Z. (2017) · Genes · doi:10.3390/genes8060151 · Cited by 445 · see citing works
Affer, M., Chesi, M., Chen, W. D., Keats, J. J., Demchenko, Y. N., Tamizhmani, K., Garbitt, V. M., Riggs, D. L., Brents, L. A., Roschke, A. V., et al. (2014) · Leukemia · doi:10.1038/leu.2014.70 · Cited by 269 · see citing works
Self-citationWalker, B. A., Wardell, C. P., Brioli, A., Boyle, E. M., Kaiser, M., Begum, D. B., Dahir, N. B., Johnson, D. C., Ross, F. M., Davies, F. E., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.13 · Cited by 181 · see citing works
Romero, O. A., Torres-Diz, M., Pros, E., Savola, S. P., Gómez, A., Morán, S., Sáez, C., Iwakawa, R., Villanueva, A., Montuenga, L. M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0799 · Cited by 164 · see citing works
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
Barwick, B. G., Neri, P. E., Bahlis, N. J., Nooka, A. K., Dhodapkar, M. V., Jaye, D. L., Hofmeister, C. C., Kaufman, J. L., Gupta, V. A., Auclair, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09555-6 · Cited by 140 · see citing works
Self-citationDutta, A. K., Fink, J. L., Grady, J. P., Morgan, G. J., Mullighan, C. G., To, L. B., Hewett, D. R., & Zannettino, A. C. W. (2018) · Leukemia · doi:10.1038/s41375-018-0206-x · Cited by 137 · see citing works
Kamoun, A., Idbaïh, A., Dehais, C., Elarouci, N., Carpentier, C., Letouzé, É., Colin, C., Mokhtari, K., Jouvet, A., Uro‐Coste, E., et al. (2016) · Nature Communications · doi:10.1038/ncomms11263 · Cited by 104 · see citing works
Mikulasova, A., Wardell, C. P., Murison, A., Boyle, E. M., Jackson, G. H., Smetana, J., Kufova, Z., Pour, L., Sandecka, V., Almasi, M., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.163766 · Cited by 101 · see citing works
MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma
Wang, D., Hashimoto, H., Zhang, X., Barwick, B. G., Lonial, S., Boise, L., Vertino, P. M., & Cheng, X. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1184 · Cited by 91 · see citing works
Kortuem, K. M., Braggio, E., Bruins, L. A., Barrio, S., Shi, C., Zhu, Y.-J., Tibes, R., Viswanatha, D. S., Votruba, P. G., Ahmann, G. J., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.1 · Cited by 54 · see citing works
Self-citationWeinhold, N., Kirn, D., Seckinger, A., Hielscher, T., Granzow, M., Bertsch, U., Egerer, G., Salwender, H. J., Blau, I. W., Weisel, K. C., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.136929 · Cited by 44 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Malard, F., Neri, P. E., Bahlis, N. J., Terpos, E., Moukalled, N. M., Hungria, V., Manier, S., & Mohty, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00529-7 · Cited by 368 · see citing works
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
Mateos, M.-V., Kumar, S., Dimopoulos, M. A., González-Calle, V., Kastritis, E., Hajek, R., De Larrea, C. F., Morgan, G. J., Merlini, G., Goldschmidt, H., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00366-3 · Cited by 291 · see citing works
Self-citationMYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies
Ahmadi, S. E., Rahimi, S., Zarandi, B., Chegeni, R., & Safa, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01111-4 · Cited by 211 · see citing works
Bustoros, M., Sklavenitis-Pistofidis, R., Park, J., Redd, R., Zhitomirsky, B., Dunford, A. J., Salem, K., Tai, Y.-T., Anand, S., Mouhieddine, T. H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00437 · Cited by 187 · see citing works
Self-citationGenomic profiling for clinical decision making in lymphoid neoplasms
de Leval, L., Alizadeh, A. A., Bergsagel, P. L., Campo, E., Davies, A. J., Doǧan, A., Fitzgibbon, J., Horwitz, S. M., Melnick, A. M., Morice, W. G., et al. (2022) · Blood · doi:10.1182/blood.2022015854 · Cited by 171 · see citing works
Self-citationOben, B., Froyen, G., Maclachlan, K. H., Leongamornlert, D., Abascal, F., Zheng-Lin, B., Yellapantula, V., Derkach, A., Geerdens, E., Diamond, B. T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22140-0 · Cited by 129 · see citing works
Boyle, E. M., Deshpande, S., Tytarenko, R., Ashby, C., Wang, Y., Bauer, M. A., Johnson, S. K., Wardell, C. P., Thanendrarajan, S., Zangari, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20524-2 · Cited by 128 · see citing works
Revealing the Impact of Structural Variants in Multiple Myeloma
Rustad, E. H., Yellapantula, V. D., Głodzik, D., Maclachlan, K. H., Diamond, B. T., Boyle, E. M., Ashby, C., Blaney, P., Gundem, G., Hultcrantz, M. L., et al. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0132 · Cited by 120 · see citing works
Self-citationGenetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications
Cardona‐Benavides, I. J., Ramón, C. D., & Gutierrez, N. C. (2021) · Cells · doi:10.3390/cells10020336 · Cited by 107 · see citing works
Skerget, S., Penaherrera, D., Chari, A., Jagannath, S., Siegel, D. S., Vij, R., Orloff, G., Jakubowiak, A., Niesvizky, R., Liles, D., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01853-0 · Cited by 95 · see citing works
Self-citationThe genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma
Vo, J. N., Wu, Y., Mishler, J., Hall, S., Mannan, R., Wang, L., Yu, N., Zhou, J. R., Hopkins, A. C., Estill, J. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31430-0 · Cited by 92 · see citing works
Self-citationLarráyoz, M., Garcia-Barchino, M. J., Celay, J., Etxebeste, A., Jiménez, M., Pérez, C., Ordóñez, R., Cobaleda, C., Botta, C., Fresquet, V. J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02178-3 · Cited by 90 · see citing works
Self-citationBoiarsky, R. P., Haradhvala, N. J., Alberge, J.-B., Sklavenitis‐Pistofidis, R., Mouhieddine, T. H., Zavidij, O., Shih, M., Firer, D. T., Miller, M. L., El‐Khoury, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33944-z · Cited by 74 · see citing works
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma
Sklavenitis-Pistofidis, R., Aranha, M. P., Redd, R. A., Baginska, J., Haradhvala, N. J., Hallisey, M., Dutta, A. K., Savell, A., Varmeh, S., Heilpern-Mallory, D., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.017 · Cited by 70 · see citing works
Accelerated single cell seeding in relapsed multiple myeloma
Landau, H. J., Yellapantula, V. D., Diamond, B. T., Rustad, E. H., Maclachlan, K. H., Gundem, G., Medina-Martinez, J. S., Ossa, J. A., Levine, M. F., Zhou, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17459-z · Cited by 68 · see citing works
Schinke, C., Poos, A. M., Bauer, M., John, L., Johnson, S., Deshpande, S., Carrillo, L. F., Alapat, D. V., Rasche, L., Thanendrarajan, S., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007217 · Cited by 67 · see citing works
Chromosomal defects in multiple myeloma
Clarke, S. E., Fuller, K. A., & Erber, W. N. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101168 · Cited by 66 · see citing works
Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?
Bolli, N., Genuardi, E., Ziccheddu, B., Martello, M., Oliva, S., & Terragna, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00189 · Cited by 57 · see citing works
Misund, K., Bruinink, D. H. O., Coward, E., Hoogenboezem, R. M., Rustad, E. H., Sanders, M. A., Rye, M. B., Sponaas, A., van der Holt, B., Zweegman, S., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01597-y · Cited by 56 · see citing works
Self-citationFOXM1 regulates glycolysis and energy production in multiple myeloma
Cheng, Y., Sun, F., Thornton, K. A., Jing, X., Dong, J., Yun, G., Pisano, M. D., Zhan, F., Kim, S. H., Katzenellenbogen, J. A., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02398-4 · Cited by 56 · see citing works
Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma
Abdallah, N. H., Baughn, L. B., Rajkumar, S. V., Kapoor, P., Gertz, M. A., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Dingli, D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2283 · Cited by 55 · see citing works
Self-citationTermini, R., Žihala, D., Terpos, E., Perez-Montaña, A., Jelínek, T., Raab, M., Weinhold, N., Mai, E. K., Grab, A. L., Corre, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1594 · Cited by 54 · see citing works
on behalf of the GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group, Garcés, J., Bretones, G., Burgos, L., Valdés‐Mas, R., Puig, N., Cedena, M., Alignani, D., Rodríguez, I., Puente, D. Á., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0883-0 · Cited by 50 · see citing works
Musto, P., Engelhardt, M. M., Caers, J., Bolli, N., Kaiser, M., van de Donk, N. W. C. J., Terpos, E., Broijl, A., de Larrea, C. F., Gay, F., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.278519 · Cited by 50 · see citing works
Robinson, M. H., Villa, N. Y., Jaye, D. L., Nooka, A. K., Duffy, A., McCachren, S. S., Manalo, J., Switchenko, J. M., Barnes, S., Potdar, S., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167629 · Cited by 48 · see citing works
Evolution and structure of clinically relevant gene fusions in multiple myeloma
Foltz, S. M., Gao, Q., Yoon, C. J., Sun, H., Yao, L., Li, Y., Jayasinghe, R. G., Cao, S., King, J. A., Kohnen, D. R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16434-y · Cited by 47 · see citing works
Welsh, S. J., Barwick, B. G., Meermeier, E. W., Riggs, D. L., Shi, C.-X., Zhu, Y. X., Sharik, M. E., Du, M. T., Rocha, L. D. A., Garbitt, V. M., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0062 · Cited by 44 · see citing works
Self-citationProgression signature underlies clonal evolution and dissemination of multiple myeloma
Shen, Y. J., Mishima, Y., Shi, J., Sklavenitis‐Pistofidis, R., Redd, R. A., Moschetta, M., Manier, S., Roccaro, A. M., Sacco, A., Tai, Y., et al. (2020) · Blood · doi:10.1182/blood.2020005885 · Cited by 44 · see citing works
Gonsalves, W. I., Broniowska, K. A., Jessen, E., Petterson, X.-M. T., Bush, A. G., Gransee, J., Lacy, M. Q., Hitosugi, T., & Kumar, S. K. (2020) · Scientific Reports · doi:10.1038/s41598-020-67105-3 · Cited by 42 · see citing works
Self-citationLi, C., Xia, J.-L., Machin, R. F., Chen, F.-P., He, Y.-J., Ashby, T., Teng, F., Xu, H.-W., Liu, D.-X., Gai, D.-Z., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146893 · Cited by 39 · see citing works
Dutta, A. K., Alberge, J.-B., Lightbody, E. D., Boehner, C. J., Dunford, A., Sklavenitis-Pistofidis, R., Mouhieddine, T. H., Cowan, A. N., Su, N. K., Horowitz, E. M., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0482 · Cited by 41 · see citing works
Ansari‐Pour, N., Samur, M., Flynt, E., Gooding, S., Towfic, F., Stong, N., Estévez, M. O., Mavrommatis, K., Walker, B. A., Morgan, G. J., et al. (2022) · Blood · doi:10.1182/blood.2022017010 · Cited by 40 · see citing works
Genome Instability in Multiple Myeloma: Facts and Factors
Aksenova, A. Y., Zhuk, A. S., Lada, A. G., Zotova, I. V., Stepchenkova, E. I., Kostroma, I. I., Gritsaev, S. V., & Pavlov, Y. I. (2021) · Cancers · doi:10.3390/cancers13235949 · Cited by 40 · see citing works
Kriegová, E., Fillerová, R., Minařík, J., Savara, J., Manakova, J., Petráčková, A., Dihel, M., Balcárková, J., Krhovská, P., Pika, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93835-z · Cited by 39 · see citing works
Chesi, M., Stein, C. K., Garbitt, V. M., Sharik, M. E., Asmann, Y. W., Bergsagel, M., Riggs, D. L., Welsh, S. J., Meermeier, E. W., Kumar, S. K., et al. (2020) · Blood Cancer Discovery · doi:10.1158/0008-5472.bcd-19-0068 · Cited by 38 · see citing works
Self-citationSmadbeck, J. B., Peterson, J. F., Pearce, K. E., Pitel, B. A., Figueroa, A. L., Timm, M., Jevremović, D., Shi, M., Stewart, A. K., Braggio, E., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0255-z · Cited by 37 · see citing works
Self-citationThe Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma
Sharma, N., Smadbeck, J. B., Abdallah, N. H., Zepeda‐Mendoza, C. J., Binder, M., Pearce, K. E., Asmann, Y. W., Peterson, J. F., Ketterling, R. P., Greipp, P. T., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0005 · Cited by 37 · see citing works
Self-citationBustoros, M., Anand, S., Sklavenitis-Pistofidis, R., Redd, R., Boyle, E. M., Zhitomirsky, B., Dunford, A. J., Tai, Y.-T., Chavda, S. J., Boehner, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30694-w · Cited by 35 · see citing works
Self-citationSuper-enhancers: A new frontier for glioma treatment
Cheng, M., Zhang, Z. W., Ji, X., Xu, Y., Bian, E., & Zhao, B. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188353 · Cited by 35 · see citing works
Awada, H. K., Thapa, B., Awada, H., Dong, J., Gurnari, C., Hari, P., & Dhakal, B. (2021) · Cells · doi:10.3390/cells10081961 · Cited by 35 · see citing works
Neri, P. E., Barwick, B. G., Jung, D., Patton, J. C., Maity, R., Tagoug, I., Stein, C. K., Tilmont, R., Leblay, N., Ahn, S., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0061 · Cited by 34 · see citing works
Self-citationPathway-Directed Therapy in Multiple Myeloma
John, L., Krauth, M. T., Podar, K., & Raab, M. (2021) · Cancers · doi:10.3390/cancers13071668 · Cited by 33 · see citing works
Genomic landscape of multiple myeloma and its precursor conditions
Alberge, J.-B., Dutta, A. K., Poletti, A., Coorens, T. H. H., Lightbody, E. D., Toenges, R., Loinaz, X., Wallin, S., Dunford, A., Priebe, O., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02196-0 · Cited by 32 · see citing works
New horizons in our understanding of precursor multiple myeloma and early interception
dos Santos, D. M. C., Toenges, R., Bertamini, L., Alberge, J.-B., & Ghobrial, I. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00755-x · Cited by 32 · see citing works
Metabolic Effects of Recurrent Genetic Aberrations in Multiple Myeloma
Bloedjes, T. A., de Wilde, G., & Guikema, J. E. J. (2021) · Cancers · doi:10.3390/cancers13030396 · Cited by 32 · see citing works
miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma
Caracciolo, D., Riillo, C., Juli, G., Scionti, F., Todoerti, K., Polerà, N., Grillone, K., Fiorillo, L., Arbitrio, M., Martino, M. T. D., et al. (2021) · Cancers · doi:10.3390/cancers13174365 · Cited by 30 · see citing works
Croucher, D. C., Richards, L. M., Tsofack, S. P., Waller, D. D., Li, Z., Wei, E. N., Huang, X. F., Chesi, M., Bergsagel, P. L., Sébag, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26598-w · Cited by 28 · see citing works
Self-citationWiedmeier, J. E., & Bergsagel, P. L. (2022) · Life · doi:10.3390/life12060812 · Cited by 28 · see citing works
Self-citationMitochondrial metabolic determinants of multiple myeloma growth, survival, and therapy efficacy
Nair, R., Gupta, P., & Shanmugam, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1000106 · Cited by 28 · see citing works
Lipid metabolic vulnerabilities of multiple myeloma
Torcasio, R., Cantafio, M. E. G., Ikeda, R. K., Ganino, L., Viglietto, G., & Amodio, N. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01174-2 · Cited by 28 · see citing works
Optical Genome Mapping Reveals the Complex Genetic Landscape of Myeloma
Giguère, A., Raymond‐Bouchard, I., Collin, V., Claveau, J., Hébert, J., & LeBlanc, R. (2023) · Cancers · doi:10.3390/cancers15194687 · Cited by 27 · see citing works
Landgren, O. (2021) · Hematology · doi:10.1182/hematology.2021000303 · Cited by 27 · see citing works
Maura, F., Landgren, O., & Morgan, G. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1395 · Cited by 26 · see citing works
Mahdipour–Shirayeh, A., Erdmann, N., Leung-Hagesteijn, C., & Tiedemann, R. E. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab413 · Cited by 25 · see citing works
Lu, X., Andersen, E., Banerjee, R. K., Eno, C., Gonzales, P. R., Kumar, S. K., Lager, A. M., Miron, P. M., Pugh, T. J., Quintero‐Rivera, F., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01286-w · Cited by 24 · see citing works
Self-citationSudha, P., Ahsan, A., Ashby, C., Kausar, T., Khera, A., Kazeroun, M. H., Hsu, C.-C., Wang, L., Fitzsimons, E., Salminen, O., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3695 · Cited by 24 · see citing works
A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity
Vià, M. D., Ziccheddu, B., Maeda, A., Bagnoli, F., Perrone, G., & Bolli, N. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000502 · Cited by 24 · see citing works
The Role of Epigenetics in the Development and Progression of Multiple Myeloma
Ismail, N. H., Mussa, A., Zakaria, N. A., Al-Khreisat, M. J., Zahidin, M. A., Ramli, N. N., Mohammad, S. N. N. A., Hassan, R., Mohd Noor, N. H., Iberahim, S., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10112767 · Cited by 22 · see citing works
The Molecular Pathogenesis of Multiple Myeloma
Bolli, N., Martinelli, G., & Cerchione, C. (2020) · Hematology Reports · doi:10.4081/hr.2020.9054 · Cited by 22 · see citing works
Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies
Visram, A., Cook, J., & Warsame, R. M. (2021) · Hematology · doi:10.1182/hematology.2021000304 · Cited by 22 · see citing works
Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma
Ortiz-Ruiz, A., Ruiz‐Heredia, Y., Morales, M. L., Aguilar-Garrido, P., García-Ortiz, A., Valeri, A., Bárcena, C., García-Martín, R., Garrido, V., Moreno, L., et al. (2021) · Cancers · doi:10.3390/cancers13071662 · Cited by 22 · see citing works
Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing
Fitzpatrick, M. J., Nardi, V., & Sohani, A. R. (2021) · Skeletal Radiology · doi:10.1007/s00256-021-03754-3 · Cited by 21 · see citing works
Nadeem, O., Aranha, M. P., Redd, R., Timonian, M., Magidson, S., Lightbody, E. D., Alberge, J.-B., Bertamini, L., Dutta, A. K., El-Khoury, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55308-5 · Cited by 20 · see citing works
Molecular Pathogenesis of Multiple Myeloma
Maura, F., & Bergsagel, P. L. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.010 · Cited by 19 · see citing works
Self-citationBruno, T., Nicola, F. D., Corleone, G., Catena, V., Goeman, F., Pallocca, M., Sorino, C., Bossi, G., Amadio, B., Cigliana, G., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002566 · Cited by 19 · see citing works
The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma
Giacomini, A., Taranto, S., Gazzaroli, G., Faletti, J., Capoferri, D., Marcheselli, R., Sciumé, M., Presta, M., Sacco, A., & Roccaro, A. M. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03217-2 · Cited by 19 · see citing works
Genomics define malignant transformation in myeloma precursor conditions
Maura, F., Bergsagel, P. L., Ziccheddu, B., Kumar, S., Maclachlan, K., Derkach, A., Garces, J.-J., Firestone, R., Braggio, E., Asmann, Y., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-01733 · Cited by 18 · see citing works
Self-citationMaura, F., Coffey, D. G., Stein, C. K., Braggio, E., Ziccheddu, B., Sharik, M. E., Du, M. T., Alvarado, Y. T., Shi, C.-X., Zhu, Y. X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48091-w · Cited by 18 · see citing works
Self-citationDavis, L. N., Walker, Z. J., Reiman, L. T., Parzych, S. E., Stevens, B. M., Jordan, C. T., Forsberg, P. A., & Sherbenou, D. W. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0256 · Cited by 17 · see citing works
Barwick, B. G., Gupta, V. A., Matulis, S. M., Patton, J. C., Powell, D. R., Gu, Y., Jaye, D. L., Conneely, K. N., Lin, Y. C., Hofmeister, C. C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2931 · Cited by 17 · see citing works
Self-citationAkkari, Y. M. N., Baughn, L. B., Kim, A., Karaca, E., Raca, G., Shao, L., & Mikhail, F. M. (2024) · Genetics in Medicine · doi:10.1016/j.gim.2023.101054 · Cited by 16 · see citing works
Petrusca, D. N., Lee, K. P., & Galson, D. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.925807 · Cited by 16 · see citing works
Saldarriaga, M. M., Darwiche, W., Jayabalan, D. S., Monge, J., Rosenbaum, C. A., Pearse, R. N., Niesvizky, R., & Bustoros, M. W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1020011 · Cited by 16 · see citing works
Saade, C., & Ghobrial, I. M. (2025) · La Presse Médicale · doi:10.1016/j.lpm.2025.104268 · Cited by 15 · see citing works
Kunz, V., Bommert, K. S., Kruk, J., Schwinning, D., Chatterjee, M., Stühmer, T., Bargou, R. C., & Bommert, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-75499-3 · Cited by 15 · see citing works
Temporal genomic dynamics shape clinical trajectory in multiple myeloma
Maura, F., Kaddoura, M., Poos, A. M., Baughn, L. B., Ziccheddu, B., Bärtsch, M.-A., Cirrincione, A., Maclachlan, K., Chojnacka, M., Diamond, B., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02292-1 · Cited by 14 · see citing works
Self-citationWDR26 and MTF2 are therapeutic targets in multiple myeloma
Sun, F., Cheng, Y., Riordan, J. D., Dupuy, A. J., Dubois, W., Pisano, M. D., Dong, J., Mock, B. A., Zhan, F., Hari, P., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01217-9 · Cited by 14 · see citing works
Zou, J., Jones, R. J., Wang, H., Kuiatse, I., Shirazi, F., Manasanch, E. E., Lee, H. C., Sullivan, R., Fung, L. M., Richard, N., et al. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01943-6 · Cited by 14 · see citing works
Pathogenic signaling in multiple myeloma
Bolomsky, A., & Young, R. M. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.01.005 · Cited by 13 · see citing works
Multiple Myeloma: Bioinformatic Analysis for Identification of Key Genes and Pathways
Saadoune, C., Nouadi, B., Hamdaoui, H., Chegdani, F., & Bennis, F. (2022) · Bioinformatics and Biology Insights · doi:10.1177/11779322221115545 · Cited by 13 · see citing works
MYC alterations in multiple myeloma: Genetic insights and prognostic impact
Cristobal‐Vargas, S., Cuadrado, M., & Gutierrez, N. C. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101177 · Cited by 12 · see citing works
Genetic Predictors of Mortality in Patients with Multiple Myeloma
Hassan, H., & Szalat, R. E. (2021) · The Application of Clinical Genetics · doi:10.2147/tacg.s262866 · Cited by 12 · see citing works
High or low? Assessing disease risk in multiple myeloma
Schmidt, T. M. (2022) · Hematology · doi:10.1182/hematology.2022000347 · Cited by 12 · see citing works
Tonon, G. (2023) · Blood · doi:10.1182/blood.2023021384 · Cited by 11 · see citing works
Lightbody, E. D., Sklavenitis‐Pistofidis, R., Wu, T., Tsuji, J., Firer, D. T., Agius, M. P., Dutta, A. K., Barr, H., Kim, S., Alberge, J.-B., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01006-0 · Cited by 11 · see citing works
Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma
Ruiz‐Heredia, Y., Ortiz-Ruiz, A., Samur, M., Garrido, V., Rufián, L., Sánchez, R., Aguilar-Garrido, P., Barrio, S., Martín, M. A., Bolli, N., et al. (2021) · Cancers · doi:10.3390/cancers13133189 · Cited by 11 · see citing works
Peat, T. J., Gaikwad, S. M., Dubois, W., Gyabaah-Kessie, N., Zhang, S., Gorjifard, S., Phyo, Z. H., Andres, M., Hughitt, V. K., Simpson, R. J., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216284 · Cited by 10 · see citing works
Self-citationWhat Is New in the Treatment of Smoldering Multiple Myeloma?
Bolli, N., Sgherza, N., Curci, P., Rizzi, R., Strafella, V., Delia, M., Gagliardi, V. P., Neri, A., Baldini, L., Albano, F., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030421 · Cited by 10 · see citing works
Byrgazov, K., Bešše, A., Kraus, M., Slipicevic, A., Lehmann, F., Driessen, C., & Bešše, L. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000602 · Cited by 10 · see citing works
Selective Enhancer Gain-of-Function Deregulates MYC Expression in Multiple Myeloma
Rahmat, M., Clement, K., Alberge, J.-B., Sklavenitis‐Pistofidis, R., Kodgule, R., Fulco, C. P., Heilpern-Mallory, D., Nilsson, K., Dorfman, D. M., Engreitz, J., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-1440 · Cited by 9 · see citing works
Genomic Instability and Replicative Stress in Multiple Myeloma: The Final Curtain?
Botrugno, O. A., & Tonon, G. (2021) · Cancers · doi:10.3390/cancers14010025 · Cited by 9 · see citing works
Evolution of Multiple Myeloma from a Genomic Perspective
Maura, F., Samur, M., & Munshi, N. (2026) · Blood · doi:10.1182/blood.2024026313 · Cited by 8 · see citing works
Ghazzaui, N., Issaoui, H., Ferrad, M., Carrion, C., Cook‐Moreau, J., Denizot, Y., & Boyer, F. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000845 · Cited by 8 · see citing works
Chojnacka, M., Diamond, B. T., Landgren, O., & Maura, F. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.01.006 · Cited by 8 · see citing works
IL-32 is induced by activation of toll-like receptors in multiple myeloma cells
Aass, K. R., Tryggestad, S. S., Mjelle, R., Kastnes, M. H., Nedal, T. M. V., Misund, K., & Standal, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1107844 · Cited by 8 · see citing works
Self-citationEpigenetic Role of Long Non-coding RNAs in Multiple Myeloma
Mehra, N., Sundaram, S., Shah, P. S., & Rao, A. K. D. M. (2025) · Current Oncology Reports · doi:10.1007/s11912-024-01623-5 · Cited by 8 · see citing works
The perspectives of interleukin-10 in the pathogenesis and therapeutics of multiple myeloma
Liu, C., Chang, C., & Huang, W. (2020) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_141_20 · Cited by 8 · see citing works
Maneix, L., Iakova, P. A., Moree, S. E., Hsu, J. I., Mistry, R. M., Stossi, F., Lulla, P., Sun, Z., Sahin, E., Yellapragada, S. V., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0255 · Cited by 8 · see citing works
Boyle, E. M., Rosenthal, A., Ghamlouch, H., Wang, Y., Farmer, P., Rutherford, M., Ashby, C., Bauer, M., Johnson, S., Wardell, C. P., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01379-y · Cited by 8 · see citing works
Gutiérrez‐González, A., del Hierro, I., & Cariaga-Martínez, A. E. (2024) · Biology · doi:10.3390/biology13110923 · Cited by 7 · see citing works
- Authors
- MMRF CoMMpass Network, Misund, K., Keane, N., Stein, C. K., Asmann, Y. W., Day, G., Welsh, S., Van Wier, S. A., Riggs, D. L., Ahmann, G., Chesi, M., Viswanatha, D. S., Kumar, S. K., Dispenzieri, A., Gonzalez-Calle, V., Kyle, R. A., O’Dwyer, M., Rajkumar, S. V., Kortüm, K. M., Keats, J. J., Fonseca, R., Stewart, A. K., Kuehl, W. M., Braggio, E., & Bergsagel, P. L.
- Affiliations
- Mayo Clinic (US)
- Translational Genomics Research Institute (US)
- National Institutes of Health (US)
- Corresponding author
- Bergsagel, P. Leif
- ORCID
- Venue
- Leukemia
- Published
- 2019-08-22
- Volume
- 34
- Issue
- 1
- Pages
- 322-326
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- PMC
- PMC6923575
- OpenAlex
- W2969224998
- Cited by
- 161
- References
- 15
- Citations by year
- 2026: 11 · 2025: 17 · 2024: 22 · 2023: 23 · 2022: 28 · 2021: 33 · 2020: 24 · 2019: 2
- FWCI
- 15.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- NORA - Norwegian Open Research Archives (submittedVersion, other-oa)
- Funders
- National Cancer Institute (U54CA224018, R01CA195688, R01CA168762, P50CA186781)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- multiple myeloma, disease progression, carcinogenesis, FOXM1, glycolysis, energy metabolism, relapsed/refractory multiple myeloma, drug resistance, genetic heterogeneity
- MeSH terms
- Humans, Multiple Myeloma, Mutation, Proto-Oncogene Proteins c-myc, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
